Abstract
Numerous studies referring to conventional chemotherapy for aggressive fibromatosis with the use of doxorubicin, cyclophosphamide, vincristin, vinblastine and other drugs have been published. Imatinib mesylate is a recently developed oral anticancer agent designed to selectively inhibit tyrosine kinases implicated in oncogenesis and it seems to represent a promising opportunity (also in first line) in the treatment of patients with advanced disease not candidate to prior surgery.
This is a preview of subscription content, log in via an institution to check access.
References
Demetri GD, von Mahren M, Blanke CD et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 346:472–480. doi:10.1056/NEJMoa020461
Drucker BJ, Talpaz M, Resta D et al (2001) Efficacy and safety of a specific inhibitor of the BCR-Abl tyrosine kinase in chronic myelogenous leukemia. N Engl J Med 344:1031–1037. doi:10.1056/NEJM200104053441401
Janinis J, Patriki M, Vini L, Aravantinos G et al (2003) The pharmacological treatment of aggressive fibromatosis: a systematic review. Ann Oncol 14:181–190. doi:10.1093/annonc/mdg064
Mace J, Biermann JS, Sondak V et al (2002) Response to extra-abdominal desmoid tumors to therapy with imatinib mesylate. Cancer 95:2373–2379. doi:10.1002/cncr.11029
Wcislo G, Szarlej-Wcislo K, Szczylik C (2007) Control of aggressive fibromatosis by treatment with imatinib mesylate. A case report and review of the literature. J Cancer Res Clin Oncol 133:533–538. doi:10.1007/s00432-007-0198-9
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ravaioli, A., Nicoletti, S., Tamburini, E. et al. Control of aggressive fibromatosis by treatment with imatinib mesylate: a step forward?. J Cancer Res Clin Oncol 135, 325–326 (2009). https://doi.org/10.1007/s00432-008-0459-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-008-0459-2